Psöriyazisli Hastalarda Sistemik Tedaviye Verilen Yanitin C-Reaktif Protein ve Nötrofil Lenfosit Orani ile İlişkisinin Deǧerlendirilmesi: Ön Çalişma


Aksu Çerman A., AKTAŞ E., ALTUNAY İ.

Turkiye Klinikleri Dermatoloji, cilt.26, sa.2, ss.71-75, 2016 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5336/dermato.2015-48846
  • Dergi Adı: Turkiye Klinikleri Dermatoloji
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.71-75
  • Anahtar Kelimeler: C-reactive protein (164-173), Inflammation, Psoriasis, Therapy
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Objective: C-reactive protein (CRP) and neutrophil lymphocyte ratio (NLR) are inflammatory markers that are known to be elevated in psoriasis. It is neccessary to develop more objective laboratuary tools in assessment of disease severity and response to therapy beside Psoriasis Area and Severity Index (PASI). Our aim in this study was to investigate the change in CRP, NLR and PASI values in psoriatic patients at 12th week of their systemic treatment. Material and Methods: PASI, CRP and NLR levels at baseline and after 12 weeks of treatment were evaluated in a total of 34 patients with chronic plaque type psoriasis using narrow band-UVB, acitretin, methotrexate, cyclosporine, etanercept, adalimumab, adalimumab + methotrexate and ustekinumab. Results: A significant decrease in CRP, NLR and PASI levels was observed at 12th week of treatment compared to the baseline (p<0.001). There was a positive correlation between the change of PASI and CRP values (p=0.009, r= 0.441). There was no significant correlation between the change of PASI and NLR (p>0.05). Greatest reduction in PASI, CRP and NLR was seen in the cyclosporin group (r2=0.24; 95% CI; 5.49-25.53; p=0.003, r2=0.34; 95% CI; 29.07-87.45; p<0.001, r2=0.13; 95% CI; 0.66-2.33; p=0.039, respectively). Conclusion: Both CRP and NLR have prognostic values in cardiovascular diseases. In psoriatic patients it is important to start the appropriate treatment that can reduce the comorbidities like cardiovascular diseases. In our study, CRP seems to be a more useful marker in determining the disease severity and monitoring the treatment in psoriatic patients. We are in opinion that these inflammatory markers along with PASI, may provide more objective and reliable during the disease follow-up.